Smith & Nephew plc vs Uranium Energy Corp — how do they compare? Smith & Nephew plc trades at $27.67 (market cap $11.63B), while Uranium Energy Corp trades at $11.65 (market cap $5.88B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Smith & Nephew plc pays a 2.85% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals.
| SNN | UEC | |
|---|---|---|
Market Cap | $11.63B | $5.88B |
Sector | Health | Energy |
52-Week High | $38.53 | $20.14 |
52-Week Low | $27.80 | $9.04 |
Enterprise Value | $14.66B | $5.40B |
Dividend Yield | 2.85% | — |
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
UEC trades at $11.89, up 3.03% today, showing volatile momentum amid mixed technical signals. The stock faces fundamental challenges with negative profitability (-513.24% net margin) despite revenue of $66.84M in 2025, while analyst sentiment remains strongly bullish with 87.5% buy ratings. Recent news highlights institutional confidence, including BlackRock's $432.68M investment in August 2026, positioning UEC to benefit from nuclear energy tailwinds.
Outlook: High-risk, high-reward play on nuclear energy growth, but current financials show significant losses. Opportunities include sector tailwinds and institutional backing; risks involve persistent unprofitability and execution challenges in scaling operations. Investors should weigh speculative growth potential against fundamental weaknesses.
Trailing returns across standard periods
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →